List view / Grid view
In this Q&A, Immunexpress Chief Executive Officer Dr Rolland Carlson and Chief Scientific Officer Dr Richard Brandon discuss key aspects for molecular diagnostic discovery and development platforms, including how to best leverage microarray and next-generation sequencing (NGS) tools.
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
Researchers at Synlogic are clearing the path for a new class of medicine – biotherapeutics based on synthetic biology, called synthetic biotics, which are created by programming or engineering bacteria to metabolise or secrete well-validated targets of disease pathophysiology. In this article, Dr Caroline Kurtz, Chief Development Officer at Synlogic, discusses how synthetic…
Within this ebook are features on synthetic biology, covering synthetic biotics and their potential to treat a wide range of diseases and conditions, while another piece examines the therapeutic directions the synthetic biology field will likely take in the future.
The researchers found that augmenting NPHP5 gene rescues cilia defects in light-sensing cells derived from ciliopathy patients.
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
Genome editing technologies could accelerate the translation of genetic advances into new therapeutics. Here, Dr Pushpanathan Muthuirulan, Research Associate at Harvard University, explores the potential of CRISPR to treat and cure genetic conditions.
This ebook includes articles on the latest Alzheimer's research on how to potentially target tau and also how new human disease models can enable the development of transformational novel therapeutics.
Included in this ebook are pieces on how an assay for the detection of sepsis was developed and a new high-throughput assay that could reveal new drugs to fight COVID-19.
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
In this issue are articles on synthetically engineered bacteria to deliver therapeutics, how single-molecule fluorescence resonance energy transfer was used to image GPCRs and a new assay to identify coronavirus drugs. Also included are pieces on vaccine development, monoclonal antibodies and neuroscience.
In this episode, experts discuss how they use ELISA assays in their research as well as the specific benefits of this kind of immunoassay.
Molecular Devices has announced a collaboration with HeartBeat.bio to develop cardiac organoids for use in drug discovery.
Researchers have found how tumours can avoid the immune system and cancer immunotherapies, including CAR T-cell therapies.
